SENSEONICS HOLDINGS INC

SENSNASDAQ

🏆 #3114 by market capEarnings Nov 3US Equity

$10.06▲ $0.22 (+2.18%)

Market closed · at close

🔔

Track SENS

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 2.2%

7d▲ 0.8%

14d▲ 10.9%

30d▲ 8.8%

ytd▲ 82.0%

1y▲ 16.1%

🏦Market Cap

$420M

Small Cap

📈Revenue Growth (YoY)

+56.9%

High Growth

📊Gross Margin

54.9%

Healthy

💵FCF Margin

-199.5%

Thin

⚖️P/S Ratio

8.5x

Elevated

Otter Score

Fair

Trading Snapshot

Day Range: $9.96 – $10.20
52-Week Range: $4.79 – $11.58
Volume: $2.90B
Avg Volume: $3.07B
Shares Outstanding: 41.8M
Next Earnings: Oct 29, 2026

Fundamentals Snapshot

Annual Revenue: $35M
Last Q Revenue: $14M
P/E Ratio: -4.3
P/S Ratio: 8.5x
EPS (TTM): $-1.89
Dividend Yield: 0.00%
Dilution (1yr): +25.2%

Why Investors Own SENS

✓High-growth profile — revenue up +39.4% YoY with expanding US Equity exposure.
✓Healthy economics — 78% gross margin and 4% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

SENSEONICS HOLDINGS INC

SENS

Financial Trends

Revenue

$35M▲ +56.9% YoY

Gross Margin

44.7%▲ +1785.0% YoY

Operating Income

−$68M▼ −8.7% YoY

Free Cash Flow

−$60M▼ −3.9% YoY

Shares Outstanding

41.7M▲ +25.2% YoY

Net Cash

−$822K▼ −$14M YoY

StockOtter · stockotter.space

About SENSEONICS HOLDINGS INC

Senseonics Holdings, Inc. operates as a medical technology enterprise, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems. These innovative solutions cater to individuals with diabetes across the United States, Europe, the Middle East, and Africa. The company's core product offerings, Eversense and Eversense XL, are advanced implantable CGM devices. They function by continuously tracking glucose levels through an under-the-skin sensor, a detachable and rechargeable smart transmitter, and an intuitive mobile application. This setup enables real-time diabetes monitoring and management for durations of up to half a year. Senseonics delivers its products and services to healthcare providers and patients alike via an extensive network of distributors and strategic fulfillment partners. Additionally, the firm maintains a collaborative agreement with the University Hospitals Accountable Care Organization. Founded in 1996, Senseonics Holdings, Inc. is headquartered in Germantown, Maryland.

🦦